sotagliflozin
AssetAlso SAR439954
Dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/SGLT2)
- Stage
- Approved
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 15
- Indications
- 43
- Trials
- 2
- Developers
Indications
15Cardiovascular death
Approved, accessdata.fda.gov, 7 Oct 2026
Chronic kidney disease
Approved, accessdata.fda.gov, 7 Oct 2026
Diabetes mellitus type 1
Approved, ema.europa.eu, 7 Oct 2026
12 more
In the full profile
- Targets and what it contains4
- Owner and partners3
- Trials43
- Evidence for its targets5
- Competitors12
- Aging relevance1
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 17 sources